X4 Pharmaceuticals (XFOR) Income from Continuing Operations (2017 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly Income from Continuing Operations came in at 23925000.0 in Q4 2025, up 39.92% YoY from 17099223.31 in Q4 2024, and up 19.76% on a QoQ basis from 29815000.0 in Q3 2025.
X4 Pharmaceuticals (XFOR) Income from Continuing Operations (2017 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Income from Continuing Operations data on file, last reported at 23925000.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 39.92% year-over-year to 23925000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 79199000.0 (down 111.48% YoY) and the FY2025 annual result came in at 79199000.0, down 111.48% from the prior year.
- Income from Continuing Operations grew to 23925000.0 in Q4 2025, from 29815000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 90833000.0 in Q2 2024 to a low of 55712000.0 in Q2 2023.
- A 5-year average of 20018950.0 and a median of 22945000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 263.04% in 2024, down 1492.02% in 2024.
- Tracing XFOR's Income from Continuing Operations over 5 years: stood at 30207000.0 in 2021, then climbed by 3.65% to 29104000.0 in 2022, then surged by 34.27% to 19130000.0 in 2023, then sank by 108.16% to 39821000.0 in 2024, then surged by 39.92% to 23925000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 23925000.0 (Q4 2025), 29815000.0 (Q3 2025), and 25741000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | -16.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.16 Mn |
| Dec 31, 2025 | -23.93 Mn |
| Sep 30, 2025 | -29.82 Mn |
| Jun 30, 2025 | -25.74 Mn |
| Mar 31, 2025 | 282,000.00 |
| Dec 31, 2024 | -39.82 Mn |
| Sep 30, 2024 | -36.70 Mn |
| Jun 30, 2024 | 90.83 Mn |
| Mar 31, 2024 | -51.77 Mn |
| Dec 31, 2023 | -19.13 Mn |
| Sep 30, 2023 | -2.31 Mn |
| Jun 30, 2023 | -55.71 Mn |
| Mar 31, 2023 | -24.02 Mn |
| Dec 31, 2022 | -29.10 Mn |
| Sep 30, 2022 | -21.59 Mn |
| Jun 30, 2022 | -21.21 Mn |
| Mar 31, 2022 | -21.97 Mn |
| Dec 31, 2021 | -30.21 Mn |
| Sep 30, 2021 | -20.18 Mn |
| Jun 30, 2021 | -19.64 Mn |